102P A multicenter retrospective cohort study comparing the efficacy and safety of lenvatinib in combination with PD-1 inhibitor with or without transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. (December 2022) - Tan, G.; Lin, J.; Wen, F.; Chi, M.; Yu, G.; Lin, Z.; Ning, Z.